Home › Research › Cognitive tests and assessment
PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country
Kittithatch Booncharoen, Akarin Hiransuthikul, Yuttachai Likitjaroen, Kammant Phanthumchinda, Sekh Thanprasertsuk, Poosanu Thanapornsangsuth. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Among 42 participants (median age: 71 years, 66.7% female), 26 (61.9%) were classified as progressors. Median (IQR) amyloid PET centiloid levels (56.7 [33.0-102.0] vs. 16.1 [5.3-61.3], p = 0.026) and Tau PET SUVR for Braak stages 3-4 (1.5 [1.2-2.1] vs. 1.1 [1.0-1.2], p <0.001) were significantly higher in progressors. Plasma p-Tau-217 (11.1 [7.1-21.0] vs. 4.0 [2.4-9.6] pg/mL, p = 0.004) and GFAP levels (206.7 [140.6-322.0] vs. 114.5 pg/mL [92.6-192.7], p = 0.003) were also significantly higher in progressors, while plasma p-Tau-181 and NfL levels showed no significant differences between groups (Figure 1). Tau PET SUVR provided the best prognostic value for 24-month progression (AUC 0.84, 95% CI 0.71-0.96), followed by plasma GFAP (AUC 0.78, 95% CI 0.62-0.94) and plasma p-Tau-217 (AUC 0.77, 95% CI 0.61-0.92) (Figure 2). Tau PET SUVR in Braak stages 3-4 is a robust marker for short-term cognitive and/or functional deterioration. Plasma p-Tau-217 not only serves a diagnosis but also has prognostic capabilities. Plasma GFAP outperforms plasma NfL in predicting short-term progression. Future studies should focus on the value of these biomarkers in long-term progression.
What this study adds
Evidence grade: Low
The record lists 42 participants. In 42 participants with mild cognitive impairment or mild dementia, higher tau PET, amyloid PET, plasma p-tau-217 and plasma GFAP were linked to progression over 24 months. Reported effect size: 66.7%; 61.9%; AUC 0.84.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Booncharoen, K., Hiransuthikul, A., Likitjaroen, Y., Phanthumchinda, K., Thanprasertsuk, S., & Thanapornsangsuth, P. (2025). PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_100227
Vancouver
Booncharoen K, Hiransuthikul A, Likitjaroen Y, Phanthumchinda K, Thanprasertsuk S, Thanapornsangsuth P. PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_100227. PMID: 41447122.
BibTeX
@article{booncharoen2025-41447122,
author = {Booncharoen, Kittithatch and Hiransuthikul, Akarin and Likitjaroen, Yuttachai and Phanthumchinda, Kammant and Thanprasertsuk, Sekh and Thanapornsangsuth, Poosanu},
title = {{PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_100227},
pmid = {41447122},
url = {https://doi.org/10.1002/alz70856_100227}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Among 42 participants (median age: 71 years, 66.7% female), 26 (61.9%) were classified as progressors.
- Median (IQR) amyloid PET centiloid levels (56.7 [33.0-102.0] vs. 16.1 [5.3-61.3], p = 0.026) and Tau PET SUVR for Braak stages 3-4 (1.5 [1.2-2.1] vs. 1.1 [1.0-1.2], p <0.001) were significantly higher in progressors.
- Plasma p-Tau-217 (11.1 [7.1-21.0] vs. 4.0 [2.4-9.6] pg/mL, p = 0.004) and GFAP levels (206.7 [140.6-322.0] vs. 114.5 pg/mL [92.6-192.7], p = 0.003) were also significantly higher in progressors, while plasma p-Tau-181 and NfL levels showed no significant differences between groups (Figure 1).
- Tau PET SUVR provided the best prognostic value for 24-month progression (AUC 0.84, 95% CI 0.71-0.96), followed by plasma GFAP (AUC 0.78, 95% CI 0.62-0.94) and plasma p-Tau-217 (AUC 0.77, 95% CI 0.61-0.92) (Figure 2).
- Tau PET SUVR in Braak stages 3-4 is a robust marker for short-term cognitive and/or functional deterioration.
Why it matters
In 42 participants with mild cognitive impairment or mild dementia, higher tau PET, amyloid PET, plasma p-tau-217 and plasma GFAP were linked to progression over 24 months. These markers may help predict short-term decline, but the study is small and did not test any treatment.
Study details
- Participants42
- Effect size66.7%; 61.9%; AUC 0.84
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 42 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Poosanu Thanapornsangsuth: h-index 5 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | World Health Organization: institution h-index 916 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41447122) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_100227
- PubMed: 41447122
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.